MedTrace Logo

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-09-23

No results posted yet for this study

Summary

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

Conditions

Interventions

DRUG

NN3201

A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Sponsors & Collaborators

  • Novelty Nobility, Inc.

    lead INDUSTRY

Principal Investigators

  • Sunil Sharma, MD · Novelty Nobility

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-03
Primary Completion
2027-08-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06805825 on ClinicalTrials.gov